Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

Acadia Pharmaceuticals stock price dropped over 15% after its drug candidate, pimavanserin, failed to meet the primary endpoint in a Phase 3 study in negative symptoms of schizophrenia. The ...

Pimavanserin’s selective action on serotonin receptors implies a strong safety profile with minimal off-target effects compared to M1/M4 agonists, which are associated with considerable side ...

Zydus Lifesciences receives USFDA approval to manufacture and market Pimavanserin Capsules and Tablets. Stock rises slightly.

Compared with patients using other antipsychotics, patients with Parkinson disease using pimavanserin had lower death rates.

To treat some of the psychosis issues associated with Parkinson’s disease, physicians often prescribe pimavanserin, an antipsychotic drug that acts within the brain to prevent hallucinations and ...

Zydus Cadila: Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Drug firm Zydus Cadila on Wednesday said it has received approval from the US health regulator to market Pimavanserin tablets, used in the treatment of certain mental disorders, in the American market ...

Zydus Cadila: Pimavanserin has been devised to treat the symptoms of Parkinson's disease including mental or mood disorder, hallucinations and delusions.

A 26-week, randomized, double-blind, placebo-controlled phase 2 study showed pimavanserin reduced negative schizophrenia symptoms in stable patients. Researchers noted that further study with ...

Pimavanserin (Nuplazid) initiation among patients with Parkinson disease was associated with greater risk of 30-day hospitalization and mortality up to one year compared with non-users.